First Immunotoxin Therapy for Many Common Solid Tumors Enters Phase I Clinical Trial

Andrew A. Skolnick
JAMA. 1993;270(19):2280. doi:10.1001/jama.1993.03510190030006.
Text Size: A A A
Published online


THE FIRST clinical trial of an immunotoxin that is genetically engineered to target a variety of common solid tumors is under way at the National Cancer Institute (NCI), Bethesda, Md. The phase I trial, which began in April, involves patients with breast or colon cancers that do not respond to conventional therapies.

Ira Pastan, MD, chief of the NCI's Laboratory of Molecular Biology and coinventor of the immunotoxin, described the development of this new type of anticancer agent at a conference in Chicago, Ill. The conference, DNA: The Double Helix— Forty Years: Perspective and Prospective, was cosponsored by The New York (NY) Academy of Sciences, The University of Illinois at Chicago, and Green College, Oxford University, England.

So far only seven of the 20 to 30 patients Pastan hopes to enroll in the trial have been treated with a protocol for determining the toxic effects of his experimental drug, B3-LysPE38.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.